Strategies for Optimal CKD-Associated Anemia Management: Interpreting and Applying Guidelines and Evidence-Based Data

On-demand Webcast

Approved for 1 AMA PRA Category 1 Credit™ and 1 Contact Hour of continuing education by the American Academy of Nurse Practitioners

This continuing nursing education activity was approved by the American Nephrology Nurses' Association, an accredited provider by the American Nurses Credentialing Center's Commission in Accreditation.

      
Jointly sponsored by the University of Cincinnati and North American Center for Continuing Medical Education, LLC

Faculty

Presenter/Q&A Cohost
Jay B. Wish, MD
Medical Director, Dialysis Program
University Hospitals Case Medical Center
Professor of Medicine
Case Western Reserve University
Cleveland, Ohio

Q&A Cohost
Ann Compton, BSN, MSN, FNP-C, CNN
Family Nurse Practitioner
Division of Nephrology
Virginia Commonwealth University Health Systems
Richmond, Virginia

Intended Learners

This activity is designed for physician assistants, nurse practitioners, and nurses.

Learning Objectives

After completing this activity, participants should be able to:

• Assess for risk and screen patients for early management of chronic kidney disease (CKD)-associated anemia
• Outline the benefits and risks associated with iron and erythropoiesis-stimulating agent (ESA) therapy in treating CKD-associated anemia patients to appropriate hemoglobin (Hgb) targets
• Describe the need for an individualized approach to CKD-associated anemia management, emphasizing quality of life (QOL)
• Apply evidence-based guidelines and recent data for optimal CKD-associated anemia diagnosis and management

Activity Overview

This on-demand webcast is available with synchronized slides and audio.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

There is no fee associated with this activity.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for these enduring materials.

Release Date: December 29, 2010

Expiration Date: August 30th, 2011

Estimated time to complete: 1 hour

For questions regarding this activity, please call 609-371-1137.

Hardware/Software Requirements
All educational activities are accessible via a computer with 650 MHz PC, 128 MB RAM, Windows or MAC operating system, Internet Explorer, Netscape, or Safari browsers. Windows Media Player, sound card, and speakers are required for streamed audio. Flash Player, sound card, and speakers are required for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

CME Accreditation (accepted for physician assistants)
The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

AANP Accreditation
This program is approved for 1.0 contact hours of continuing education by the American Academy of Nurse Practitioners. Program ID 1008238.

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

ANNA Accreditation
This continuing nursing education activity was approved by the American Nephrology Nurses' Association, an accredited provider by the American Nurses Credentialing Center's Commission in Accreditation.

Independent Clinical Reviewer Lynda Anne Szczech, MD, MSCE, Associate Professor, Division of Nephrology, Duke University Medical Center, Durham, North Carolina

Planning Committee
The planning committee comprises Jay B. Wish, MD, Ann Compton, MSN, FNP-C, CNN, Lynda Anne Szczech, MD, MSCE; Kay Weigand, University of Cinicnnati; and Randy Robbin, Mike Kearney, Emilie McCardell, John Savage, and Alicia Rybovic, NACCME.

Financial Disclosure and Conflicts of Interest
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are indentified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Wish: Consultant—Affymax; Scientific Advisor—Affymax, AMAG; Promotional Speakers' Bureau—Amgen, AMAG
Ms. Compton: Promotional Speakers' Bureau—Amgen, Genzyme
Dr. Szczech: Grant/Research Support—Amgen, Innocoll Pharmaceuticals, Genzyme, GlaxoSmithKline, Luitpold Pharmaceuticals, Pfizer, Roche Diagnostic; Consultant—Affymax, Akayada, Amgen, ASN, AstraZeneca, Baxter, DAVITA, FMC-NA, Fresenius, Gilead, Kuhura Chemical, Merck, Roche, Rockwell; Advisory Board—Sandoz, Amgen, Fresenius
Ms. Weigand, Mr. Robbin, Mr. Kearney, Ms. McCardell, and Mr. Savage have disclosed no relevant financial relationships with any commercial interests.
Ms. Rybovic: Stock Shareholder—Novo Nordisk, Amgen.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations. The faculty has disclosed the following off-label/unapproved use(s) of drugs and/or devices will be discussed: the use of epoetin alfa and darbepoetin alfa extended dosing in the treatment of CKD-induced anemia.

Privacy Policy
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate reporting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2010 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing medical education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

Grant Support
Supported by an educational grant from Centocor Ortho Biotech Inc.